Second-line docetaxel in patients with relapsed esophagogastric adenocarcinoma

A phase III study presented as a late breaking abstract at the tenth annual Gastrointestinal Cancers Symposium (24-26 January, 2013) in San Francisco, showed that second-line treatment with docetaxel results in longer overall survival compared with active symptom control in patients with advanced esophagogastric cancer whose disease progressed despite first-line chemotherapy. While this strategy is already widely used, this UK study provides more evidence of survival benefit from second-line therapy with docetaxel. Read more here.